Merck's $1B Google Cloud AI Deal and New CMS Reimbursement Shift Clinical AI Budgets

Merck–Google Cloud: $1B Platform Deal Sets Enterprise AI Procurement Benchmark

In April 2026, Merck and Google Cloud announced a multi-year partnership valued at up to $1 billion to deploy an agentic AI platform across 75,000 employees spanning R&D, manufacturing, commercial, and corporate functions. The platform runs on Google Cloud's Gemini Enterprise and digitizes data while embedding AI into end-to-end operations.

For health system CIOs and CFOs, this is a bellwether. The transaction size and multi-function scope establish what full-stack AI transformation contracts look like in regulated healthcare. It validates hyperscaler-centric strategies—Google Cloud Gemini, Microsoft Azure, AWS—as the default AI infrastructure for regulated data, multi-modal models, and enterprise governance. Large health systems and payers are already following this pattern, and Merck's deal pushes AI conversations from point-solution pilots toward platform agreements in the hundreds of millions over multiple years.

This raises the competitive bar. Specialized clinical AI vendors—Tempus AI, Viz.ai, Aidoc, Abridge—must now run on or tightly integrate with hyperscaler AI stacks. EHR incumbents Epic Systems and Oracle Health increasingly sit atop these cloud platforms, and buyers will demand seamless integration among EHR, AI services, and underlying hyperscaler infrastructure.

The procurement implications are immediate. Health systems contemplating AI transformation will be benchmarked against Merck's up-to-$1 billion, multi-year commitment. This legitimizes nine-figure, multi-year AI platform contracts that bundle infrastructure, models, and co-development. CFOs will scrutinize total cost of ownership and insist on measurable ROI across clinical, operational, and commercial workflows, mirroring emerging evaluation dimensions: clinical efficacy, interoperability, cybersecurity, AI governance, TCO, and vendor viability.

Deals at this scale require explicit AI governance, model transparency, and regulatory alignment—now non-negotiable evaluation gates alongside cybersecurity. Buyers will demand model documentation, training data provenance, bias testing, and post-deployment monitoring plans in RFPs. They will negotiate new contractual frameworks for generative and agentic AI—covering model drift, liability, patient consent—before committing multi-year spend.

Bunkerhill Health: FDA Clearance Plus CMS Reimbursement Creates Revenue-Generating AI

Bunkerhill Health obtained FDA clearance for AI algorithms that evaluate coronary artery calcium and aortic valve calcium on contrast-enhanced chest CTs. CMS established a new national billing code and associated payment for these AI services under the Hospital Outpatient Prospective Payment System, effective April 1, 2026. This is the first AI cardiovascular analysis to achieve dedicated reimbursement outside traditional imaging pathways.

Dedicated CMS reimbursement means hospitals can bill and get paid for AI-augmented CT interpretations, rather than absorbing costs as part of imaging bundles. This materially changes ROI models: AI becomes a new reimbursed service line, not just an efficiency tool. Radiology and cardiology departments can now build P&Ls that include AI-driven revenue, not just savings.

The regulatory signal is significant. This is the first example of AI cardiovascular analysis with its own national code outside legacy imaging categories, indicating CMS' willingness to create dedicated reimbursement pathways for AI services. More broadly, the 2026 Medicare Physician Fee Schedule explicitly favors AI-augmented services that demonstrate efficiency and outcomes, creating strong financial incentives for AI adoption across Medicare and Medicaid.

Competitors in cardiovascular imaging AI—HeartFlow, Cleerly, and others—compete in adjacent areas like FFR-CT and plaque analysis, but Bunkerhill holds the first-mover advantage with dedicated CMS AI cardiovascular analysis reimbursement outside traditional imaging. Any rival will need equivalent FDA clearance and a CMS code to match its monetization model. Broader imaging AI vendors like Aidoc, Viz.ai, and Gleamer typically bill via existing imaging CPT codes, per-use SaaS fees, or bundled contracts rather than dedicated CMS AI codes. Bunkerhill's reimbursement structure pressures competitors to pursue their own dedicated codes or risk offering non-reimbursed tools in a market where some AI is directly paid for.

What Enterprise Buyers Should Do Next

For budgeting, factor in nine-figure, multi-year AI platform commitments as the new normal for enterprise-scale clinical AI. Evaluate whether point solutions can integrate with your chosen hyperscaler stack—Google Cloud, Azure, or AWS—and whether vendors can provide governance, transparency, and compliance frameworks that satisfy new procurement gates.

For reimbursement-driven AI, prioritize vendors with FDA clearance and dedicated CMS billing codes. Bunkerhill's cardiovascular AI demonstrates that AI can shift from cost center to revenue generator when reimbursement is established. Radiology, cardiology, and other imaging departments should model incremental reimbursement per study and downstream procedure optimization when evaluating AI investments.

For risk management, demand explicit AI governance plans, model documentation, bias testing, and post-deployment monitoring in every RFP. Negotiate contractual frameworks that address model drift, liability, and patient consent before signing multi-year agreements. The procurement bar has moved from "does it work?" to "can we govern it, bill for it, and integrate it at scale?"